Latest news
Latest publications
- Noble J, Anglicheau D, Blancho G, Bertrand D, Couzi L, Durrbach A, Grimbert P, Kamar N, Le Meur Y, Moulin B, Rostaing L. |LS|Early conversion to belatacept post-transplantation: state of the art and expert opinion|RS|. Nephrol Ther. 2025 Mar 11;21(1):37–47. DOI: 10.1684/ndt.2025.104
- Le Rochais M, Brahim I, Zeghlache R, Redoulez G, Guillard M, Le Noac’h P, Castillon M, Bourhis A, Uguen A. Automated classification of tertiary lymphoid structures in colorectal cancer using TLS-PAT artificial intelligence tool. Sci Rep. 2025 Mar 21;15(1):9845. DOI: 10.1038/s41598-025-94664-0
- Morin L, Autier B, Hemon P, Le Gallou S, Roussel M, Dion S, Lecureur V. Protocol for phenotyping mouse myeloid and lymphoid cells by mass cytometry. STAR Protoc. 2025 Mar 21;6(1):103684. DOI: 10.1016/j.xpro.2025.103684
- Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, Forcade E, Meyer A, Jorgensen C, Bigenwald C, Cornec D, Sibilia J, Choquet S, Martin T, Belot A, Jouret M, Bitoun S, Amoura Z, Hermine O, Mariette X, Donnadieu E, Avouac J, Club for Innovative Immunotherapies in Immune-mediated Inflammatory diseases (C3I). CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol. 2025 Mar 26;S2665-9913(24)00377–1. DOI: 10.1016/S2665-9913(24)00377-1
- Beydon M, Nguyen Y, Gordon R, Foulquier N, Bouillot C, Hammitt KM, Bowman SJ, Mariette X, Cornec D, McCoy SS, Seror R. A systematic review of clinical trial designs and outcome measures in Sjögren’s disease randomized trials. J Rheumatol. 2025 Apr 1;jrheum.2024-1012. DOI: 10.3899/jrheum.2024-1012
The UMR1227 'B Lymphocytes and Autoimmunity' brings together several clinical entities around the immunology laboratory.
Rheumatology, haematology, nephorology and odontology for a scientific project articulated around two main complementary and interconnected axes: an axis dedicated to the understanding of the mechanisms that govern the functional orientation of B cells in autoimmunity, and a translational axis aiming at developing new tools to improve the efficiency of B-cell targeting immunotherapies, while working on a better stratification of patients, a better understanding of the mode of action of these therapies, and the development of these therapies and innovative therapeutic strategies.
Key figures
They support us
